Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP2 | P08253 | 3/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | SAT1 | P21673 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL17746584 | 0.90 | MMP1 (0.39) | MMP1MMP2MMP8MMP3MMP9 | |
| Phosphoric Acid SCHEMBL17746583 | 0.83 | MMP1 (0.34) | MMP1MMP2MMP8MMP3MMP9 | |
| SCHEMBL37249 | 0.78 | — | — | |
| SCHEMBL5015421 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL1579364 | 0.74 | — | — | |
| SCHEMBL17746590 | 0.74 | CA2 (0.34) | CA12CA1CA2CA9 | |
| Acetic Acid SCHEMBL5547293 | 0.74 | — | — | |
| Diethylamine SCHEMBL28794397 | 0.73 | TP53 (0.50) | MMP1MMP2MMP8MMP3MMP9 | |
| Diethylamine SCHEMBL28794398 | 0.73 | TP53 (0.50) | MMP1MMP2MMP8MMP3MMP9 | |
| Thiosulfuric Acid SCHEMBL5551548 | 0.70 | CA2 (0.32) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060246438-A1 | Methods for the chemical and physical modification of nanotubes, methods for linking the nanotubes, methods for the directed positioning of nanotubes, and uses thereof | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2006-11-02 | — | — | US | disclosed |
| EP-1549662-A1 | METHODS FOR THE CHEMICAL AND PHYSICAL MODIFICATION OF NANOTUBES, METHODS FOR LINKING THE NANOTUBES, METHODS FOR THE DIRECTED POSITIONING OF NANOTUBES, AND USES THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2005-07-06 | — | — | EP | disclosed |
| US-6828148-B2 | Compound for use in the treatment of infections, arthritis, artherosclerosis, restenosis, psoriasis, cancer and leukemia | GENE SHEARS PTY. LIMITED (AU) | 2004-12-07 | — | — | US | disclosed |
| WO-2004020450-A1 | METHODS FOR THE CHEMICAL AND PHYSICAL MODIFICATION OF NANOTUBES, METHODS FOR LINKING THE NANOTUBES, METHODS FOR THE DIRECTED POSITIONING OF NANOTUBES, AND USES THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-03-11 | — | — | WO | disclosed |
| EP-0837933-A4 | OPTIMIZED MINIZYMES AND MINIRIBOZYMES AND USES THEREOF | COMMW SCIENT IND RES ORG (AU) | 2003-05-21 | — | — | EP | disclosed |
| US-20020155454-A1 | Miniribozymes active at low magnesium ion concentrations | GENE SHEARS PTY. LIMITED (AU) | 2002-10-24 | — | — | US | disclosed |
| US-6277634-B1 | HYBRIDIZED WITH TARGET RNA TO BE CLEAVED; MEDICAL DIAGNOSIS OR GENE THERAPY, DRUGS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 2001-08-21 | — | — | US | disclosed |
| WO-2000039146-A1 | MINIRIBOZYMES ACTIVE AT LOW MAGNESIUM ION CONCENTRATIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-07-06 | — | — | WO | disclosed |
| US-6001648-A | NUCLEOTIDE SEQUENCE WHICH HYBRIDIZES TO AND CLEAVES TARGET RNA SEQUENCE; FOR DIAGNOSTIC OR THERAPEUTIC AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1999-12-14 | — | — | US | disclosed |
| EP-0837933-A1 | OPTIMIZED MINIZYMES AND MINIRIBOZYMES AND USES THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1998-04-29 | — | — | EP | disclosed |
| WO-1996040906-A1 | OPTIMIZED MINIZYMES AND MINIRIBOZYMES AND USES THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155454-A1 | Miniribozymes active at low magnesium ion concentrations | EMG1, RNASE1, MMEL1 | MMP1 2152/4885MMP2 443/4885MMP8 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.